W81XWH-21-OPORP-CTA: DOD Orthotics and Prosthetics Outcomes, Clinical Trial Award
Closed
This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2021.
Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 4 awards worth $15.0 million in total. Applications closed on July 29, 2021.
From the official notice on Grants.gov, last changed April 1, 2021. Checked November 7, 2026.
- Total funding$15.0 million
- Expected awards4
- Cost sharingNot required
- Funding typeCooperative Agreement, Grant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| HT9425-23-OPORP-CTA | April 27, 2023 | Closed July 12, 2023 | Closed |
| W81XWH-22-OPORP-CTA | March 22, 2022 | Closed June 1, 2022 | Closed |
Key dates
| Posted | April 1, 2021 |
|---|---|
| Deadline | July 29, 2021 |
| Archived by Grants.gov | August 28, 2021 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Most of the program's money (59% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The FY21 OPORP CTA is intended to support the implementation of clinical trials with the potential to have a significant impact on improving the health and well-being of Service Members and military beneficiaries, Veterans, and other individuals with limb loss and/or limb impairment. This award mechanism supports clinical trials that evaluate orthoses and/or prostheses using patient-centric outcomes for the purpose of generating clinically useful evidence to enhance and optimize patient outcomes. Proposed projects may range from small proof-of-concept trials to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials in relevant patient populations. Alternate research designs (e.g., pragmatic and practice-based evidence trials) that provide evidence for adoption of tested orthotic and/or prosthetic devices in real-world clinical practice and inform clinical or policy decisions are particularly encouraged. The FY21 OPORP is also interested in multidisciplinary projects that address strategies to mitigate secondary injuries. Studies proposing or evaluating rehabilitation strategies must indicate how the rehabilitation may improve the orthotic or prosthetic device outcome when compared to standard of care. The FY21 OPORP CTA offers funding for two Funding Levels (Refer to Section II.D.5, Funding Restrictions). Only one Funding Level category may be chosen per application, and the choice of application category is at the discretion of the applicant. The following are generalized descriptions of the scope of research appropriate for each Funding Level: • Funding Level 1 supports pilot and early-stage clinical trials that are exploratory and involve limited human exposure (e.g., small sample size), with the potential to make significant advancements toward clinical translation. Preliminary data are encouraged but not required for this Funding Level. • Funding Level 2 supports large clinical trials that have the potential to make significant advancement toward clinical translation. Proposed projects may include large-scale trials that, if successful, will produce high-quality outcomes with robust, statistically relevant participant numbers to provide strong, definitive support for evidence-based practice and/or have the potential to drive changes in clinical practice. Pragmatic clinical studies, randomized controlled trials, and comparative effectiveness studies are welcome and encouraged.
Who has won Military Medical Research and Development grants before
From fiscal 2021 to 2025, Military Medical Research and Development (12.420) awarded $6.9 billion across 5,470 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Maryland | 81 | $546 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 139 | $166 million |
| The Johns Hopkins University | Maryland | 157 | $153 million |
| The Regents of the University of California, San Francisco | California | 113 | $147 million |
| Duke University | North Carolina | 86 | $123 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is W81XWH-21-OPORP-CTA still open?
No. It closed on July 29, 2021. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).
Who can apply for DOD Orthotics and Prosthetics Outcomes, Clinical Trial Award?
Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.
What is the deadline for DOD Orthotics and Prosthetics Outcomes, Clinical Trial Award?
Closed July 29, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $15.0 million in total across about 4 awards.
Who has won Military Medical Research and Development grants before?
The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.